期刊文献+

文拉法新与舍曲林治疗抑郁症疗效的Meta分析 被引量:2

Meta-analysis of Clinical Efficacy of Venlafaxine vs.Sertaline in the Treatment of Depression
下载PDF
导出
摘要 目的:评价文拉法新与舍曲林治疗抑郁症疗效的差异。方法:对6项符合纳入标准的研究应用循证医学方法评价文拉法新与舍曲林治疗抑郁症疗效有效率、以及症状学变化的差异。结果:文拉法新组的有效率(122/177 vs 128/179,OR=1.22,95%CI:0.77~1.93,Z=0.86,P>0.05)与曲林组相似,但是文拉法新组在第1周末(WMD:-1.57,95%CI:-2.98^-0.15,Z=2.17,P=0.03)和第2周末(WMD:-1.53,95%CI:-2.83^-0.23,Z=2.30,P=0.02)症状改善明显于舍曲林,而在第6周末相似(WMD:0.13,95%CI:-0.91~1.17,Z=0.25,P=0.81)。结论:文拉法新与舍曲林治疗抑郁症有效率相似,但前者症状改善前2周改善比较快。 OBJECTIVE: To evaluate the efficacy of welafaxine v.sertaline in the treatment of depression.METHODS: 6 studies meeting our criteria were analyzed with the use of evidence-based medicine method,with the curative efficacy such as the effective rate and the change in symptoms of welafaxine vs.sertaline evaluated comparatively.RESULTS: There were no significant differences in effective rate between welafaxine and sertaline(122/177 vs.128/179,OR=1.22,95% CI: 0.77~1.93,Z=0.86,P0.05),whereas the symptom improvement in venlafaxine-treated group at 1st weekend(WMD:-1.57,95%CI:-2.98^-0.15,Z=2.17,P=0.03) and 2nd weekend(WMD:-1.53,95%CI:-2.83^-0.23,Z=2.30,P=0.02) were significantly better than in sertraline group but this difference at 6th weekend was not significant(WMD: 0.13,95%CI:-0.91~1.17,Z=0.25,P=0.81).CONCLUSION: The venlafaxine is similar to sertraline in effective rate for depression,but symptom improvement appeared earlier for the venlafaxine-treated patients in the initial two weeks' treatment of depression.
出处 《中国医院用药评价与分析》 2010年第1期47-49,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 文拉法新 舍曲林 抑郁症 META分析 Venlafaxine Sertraline Depression Meta-analysis
  • 相关文献

参考文献10

二级参考文献49

共引文献73

同被引文献24

  • 1甘景梨,金卫东,钱敏才,胡纪明,冯斌.文拉法辛与SSRI治疗抑郁症痊愈率的循证医学研究[J].山东精神医学,2006,19(1):6-8. 被引量:18
  • 2胡萌,李臻.噻奈普汀药理研究和临床应用进展[J].广东医学,2007,28(7):1192-1193. 被引量:7
  • 3Kessler R C, Berglund P, Demler O, et al. The epidemiology of major depressive disorder sresuhs from the national comorbidity survey replication (NCS-R)[J]. JAMA, 2003, 89 (2):3095- 3105.
  • 4Meijer W, Heerdink E, Leufkens H, et al. Incidence and determinants of long-term use of antidepressants [J]. Eur J Clin Pharmacol, 2004,60(1): 57-61.
  • 5The committee formedical products for human use. CHMP meeting on paroxetine and other SSRIs [EB/OL]. http:// medicalnewstoday. com/medicalnew, 2005-01-10.
  • 6Hammad F A, Laughren T, Raeoosin J. Suicidality in pediatric patients treated with antidep ressand drugs [J]. Arch Gen Psychiatry, 2006,63:332-339.
  • 7Simon G E,Savarino J, Operskalski B, et al. Suicide risk duringantidep ressant treatment[J]. Am J Psychiatry, 2006,163 : 41-47.
  • 8Thase M E,Entsuah A R,Rudolph R L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors [J]. Bri J Psychiatry,2001,178: 234-241.
  • 9Cipriani A, Furukawa T A, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants:a multiple-treatments meta-analysis [ J ]. Lancet, 2009, 373 (9665):746-748.
  • 10James W, James F, Keith T. Bupropion for major depressive disorder:Pharmaeokinetie and formulation considerations[J]. Clin Ther,2005,27(11):1685-1686.

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部